Skip to main content

BICYCLE THERAPEUTICS PLC

For the period ended Mar 31, 2026. Filed Apr 30, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed Apr 30, 2026

BCYC$3.69-2.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Shareholders’ Equity

(In thousands, except share data)

​​​​​​​​​​​​​​​​​​
​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · Accumulated · ​ · ​ · ​ · ​ · ​ · ​
​ · ​ · ​ · ​ · ​ · ​ · ​ · Additional · ​ · Other · ​ · ​ · ​ · ​ · Total
​ · ​ · Ordinary Shares · ​ · Paid‑in · ​ · Comprehensive · ​ · Accumulated · ​ · Shareholders’
​ · ​ · Shares · ​ · Amount · ​ · Capital · ​ · Income (Loss) · ​ · Deficit · ​ · Equity
Balance at December 31, 2025​69,367,896​$894​$1,512,339​$(3,505)​$(899,751)​$609,977
Issuance of ADSs upon exercise of share options​3,861​​—​​7​​—​​—​​7
Issuance of ADSs upon settlement of restricted share units​335,269​​5​​—​​—​​—​​5
Share-based compensation expense​—​​—​​6,930​​—​​—​​6,930
Foreign currency translation adjustment​—​​—​​—​​(1,774)​​—​​(1,774)
Net loss​—​​—​​—​​—​​(60,825)​​(60,825)
Balance at March 31, 2026​69,707,026​​899​​1,519,276​​(5,279)​​(960,576)​​554,320
​​​​​​​​​​​​​​​​​​
​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · Accumulated · ​ · ​ · ​ · ​ · ​ · ​
​ · ​ · ​ · ​ · ​ · ​ · ​ · Additional · ​ · Other · ​ · ​ · ​ · ​ · Total
​ · ​ · Ordinary Shares · ​ · Paid‑in · ​ · Comprehensive · ​ · Accumulated · ​ · Shareholders’
​ · ​ ​ ​ · Shares · ​ · Amount · ​ · Capital · ​ · Income (Loss) · ​ · Deficit · ​ · Equity
Balance at December 31, 2024​69,061,418​$890​$1,472,842​$119​$(680,791)​$793,060
Issuance of ADSs upon settlement of restricted share units​140,937​​2​​—​​—​​—​​2
Share-based compensation expense​—​​—​​9,605​​—​​—​​9,605
Foreign currency translation adjustment​—​​—​​—​​(1,580)​​—​​(1,580)
Net loss​—​​—​​—​​—​​(60,754)​​(60,754)
Balance at March 31, 2025​69,202,355​​892​​1,482,447​​(1,461)​​(741,545)​​740,333
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.